Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 2/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804070 | 0.95 | PPARG (0.39) | PPARGPPARAPPARDFFAR4RARA | |
| SCHEMBL19804400 | 0.93 | PPARG (0.38) | PPARGPPARAPPARDCSF1RTSHR | |
| SCHEMBL19797021 | 0.90 | TSHR (0.32) | PPARGPPARAPPARDTSHR | |
| SCHEMBL19804351 | 0.90 | PPARG (0.38) | PPARGPPARAPPARDFFAR4RARA | |
| SCHEMBL19804278 | 0.89 | FFAR4 (0.34) | FFAR4CA1CA2 | |
| SCHEMBL20171722 | 0.88 | RARA (0.32) | PPARGPPARAPPARDRARARARB | |
| SCHEMBL19796640 | 0.87 | TSHR (0.33) | PPARGPPARAPPARDFFAR4RARA | |
| SCHEMBL19804491 | 0.87 | PPARG (0.37) | PPARGPPARAPPARDCSF1RSLC6A9 | |
| SCHEMBL20171741 | 0.86 | PPARG (0.32) | PPARGPPARAPPARDFFAR4RARA | |
| SCHEMBL19804368 | 0.86 | CYP3A4 (0.41) | PPARGPPARAPPARDFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | PPARG 3314/4885PPARA 3672/4885PPARD 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.